Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Repurposing the third-generation EGFR inhibitor osimertinib to synergize with paclitaxel and extend survival in anaplastic thyroid cancer.

BACKGROUND Anaplastic thyroid cancer (ATC) is a highly aggressive malignancy with limited therapeutic options and poor prognosis. This study aimed to identify effective targeted agents and evaluate their therapeutic potential in combination with paclitaxel. METHODS High-throughput drug sensitivity and resistance scre...

Ran Jie, Xia-Wei Shen · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.